| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2016-10-03 | Allergan's Anda (Ireland) | Teva Pharmaceutical Industries (Israel) | $500 million | Generics Distribution |
| 2016-09-28 | 4SC's immunology portfolio | Immunic (Germany) | undisclosed | Autoimmune diseases Immunological diseases |
| 2016-09-23 | Medivation (USA - CA) | Pfizer (USA - NY) | $14 billion (€ 12.36 billion) | Cancer - Oncology |
| 2016-09-20 | Akarna Therapeutics (UK - USA - CA) | Allergan (Ireland) | up-front payment of $50 million and potential clinical, regulatory and commercial milestone payments | Hepatic diseases Liver diseases |
| 2016-09-14 | Vitae Pharmaceuticals (USA - PA) | Allergan (Ireland) | $639 million | Autoimmune diseases Dermatological diseases |
| 2016-09-13 | InterHealth Nutraceuticals (USA - CA) | Lonza (Switzerland) | up to $ 300 million | Nutrition Nutraceuticals |
| 2016-09-12 | Raptor Pharmaceutical (USA - CA) | Horizon Pharma (Ireland) | $800 million (€711.6 million) | Rare diseases |
| 2016-09-12 | GSK's anaesthesia portfiolo and thrombosis business | Aspen Global Incorporated (South Africa) | £180 million plus milestones of up to £100 million | |
| 2016-09-06 | RetroSense Therapeutics (USA - MI) | Allergan (Ireland) | $60 million and undisclosed milestone payments | Ophtalmological diseases Gene therapy |
| 2016-09-01 | Cynapsus Therapeutics (Canada) | Sumitomo Dainippon Pharma (Japan) Sunovion (USA) | $ 624 million (€ 559 million) | CNS diseases Neurological diseases |
| 2016-09-01 | VRL Laboratories (USA - CO) | Eurofins Scientific (Luxembourg) | undisclosed | Technology - Services |
| 2016-08-26 | Transition Therapeutics (Canada) | Opko Health (USA - FL) | $60 million | CNS diseases Metabolic diseases Hormonal diseases |
| 2016-08-24 | Astra Zeneca's late-stage small molecule antibiotics business | Pfizer (USA - NY) | up to $1.3 billion | Infectious diseases |
| 2016-08-15 | stake in Isomerase Therapeutics (UK) | Neurovive Pharmaceutical (Sweden) | £ 0.55 million (€ 0.72 million) | |
| 2016-08-12 | Flamel Technologies (France) | Avadel Pharmaceuticals (Ireland) | Specialty pharma |
|
| 2016-08-11 | ForSight VISION5 (USA - CA) | Allergan (Ireland) | $95 million upfront payment and launch milestone payment | Ophtalmological diseases |
| 2016-08-05 | Meda (Sweden) | Mylan (USA - PA) | $ 9.9 billion | OTC generics |
| 2016-08-02 | Allergan's generic business (Ireland) | Teva Pharmaceutical Industries (Israel) | $40.5 billion | Generic drugs |
| 2016-08-01 | Bamboo Therapeutics (USA - NC) | Pfizer (USA - NY) | up to $ 645 million | Rare diseases Neuromuscular diseases Gene therapy |
| 2016-07-27 | FirstString Research (USA - SC) | Relief Therapeutics (Switzerland) | undisclosed |
